1,582,027 2,420,837
Accrued compensation 715,036 941,300
Deferred revenue, current portion 1,916,669 4,864,833
Total current liabilities 5,474,714 9,564,705
Capital lease obligations and notes
payable, net of current portion 180,371 275,126
Deferred rent, net of current portion 1,597,647 1,966,628
Deferred revenue, net of current portion 6,388,886 12,443,087
Total liabilities 13,641,618 24,249,546
Stockholders' equity:
Preferred stock of $.01 par value -
authorized 10,000,000 shares;
Series A Convertible; issued and
outstanding 4,997 shares as of
December 31, 2007 and June 30, 2007 50 50
Common stock of $.01 par value -
authorized 150,000,000 shares; issued
and outstanding 85,204,169 and
85,126,915 shares as of December 31,
2007 and June 30, 2007, respectively 852,042 851,269
Additional paid-in capital 207,648,737 205,875,438
Accumulated other comprehensive income 62,098 -
Accumulated deficit (197,337,143) (188,195,069)
Total stockholders' equity 11,225,784 18,531,688
Total liabilities and stockholders'
equity $24,867,402 $42,781,234
'/>"/>SOURCE Palatin Technologies, Inc. Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 Related biology technology :1.
Palatin Technologies to Report Third Quarter, Fiscal Year 2008 Financial Results; Teleconference and Webcast on May 13th2.
Palatin Technologies, Inc. Reports Positive Results of a Phase I Clinical Study With PL-3994 for the Treatment of Congestive Heart Failure3.
Palatin Technologies to Report Second Quarter, Fiscal Year 2008 Financial Results; Teleconference and Webcast on February 11th4.
Palatin Technologies, Inc. Reports Fiscal Year 2008 First Quarter Results; Teleconference and Webcast to be Held on November 9, 20075.
Palatin Technologies to Report Fiscal Year 2008 First Quarter Results; Teleconference and Webcast on November 9, 20076.
Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2007 Results; Teleconference and Webcast to be held on September 18, 20077.
Palatin Technologies Refutes Competitive Technologies Contention of Material Breach8.
Palatin Technologies Announces Reacquisition of Full Rights to Bremelanotide Program9.
Veran Medical Technologies Secures $4.75M in First Institutional Funding10.
Neurobiological Technologies Reports Third Quarter Financial Results11.
InSet Technologies Appoints Jon Tremmel to its Board of Directors